Current Management of HBV/HDV Coinfection and Future Perspectives

Current Hepatitis Reports

Volumn 14, Issue 4, 2015, Pages 284-292

  Wranke, A ^a   Heidrich, B ^a,b,c   Hardtke, S ^d   Wedemeyer, H ^a,b,d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b German Center for Infection Research (DZIF) Partner Side HepNet Study House   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d HepNet Study House   (Germany)

Author keywords

Anti HDV IgM; BEA score; Epidemiology; HBsAg; HDAg; Hepatitis delta; HIDIT; Interferon; Late relapser

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; FAMCICLOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LAMIVUDINE; LONAFARNIB; MYRCLUDEX B; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA INTERFERON; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIBODY DETECTION; ANTIGEN DETECTION; ANTIVIRAL THERAPY; DELTA AGENT HEPATITIS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS DELTA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LIVER BIOPSY; LIVER TRANSPLANTATION; MIXED INFECTION; MONOTHERAPY; PATHOGENESIS; PRENYLATION; PREVALENCE; PROGNOSIS; RELAPSE; REVIEW; SUPERINFECTION; TREATMENT DURATION; VACCINATION; VIRAL CLEARANCE; VIRION; VIRUS DETECTION; VIRUS GENOME; VIRUS LOAD; VIRUS MORPHOLOGY; VIRUS TRANSMISSION;

EID: 84973582080     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-015-0280-8     Document Type: Review

References (96)

1. Cross TJ, Rizzi P, Horner M, Jolly A, Hussain MJ, Smith HM, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in south London. J Med Virol. 2008;80(2):277–82.
2. Manesis EK, Vourli G, Dalekos G, Vasiliadis T, Manolaki N, Hounta A, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013;59(5):949–56. An interesting study showing that HDV infection is a rapidly progressive disease and that interferon-based treatment may alter its course.
3. Rizzetto M. The delta agent. Hepatology. 1983;3(5):729–37.
4. Taylor JM. Virology of hepatitis D virus. Semin Liver Dis. 2012;32(3):195–200.
5. Deny P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades? Curr Top Microbiol Immunol. 2006;307:151–71.
6. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378(9785):73–85.
7. Radjef N, Gordien E, Ivaniushina V, Gault E, Anais P, Drugan T, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol. 2004;78(5):2537–44.
8. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7(1):31–40.
9. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015.
10. Han M, Littlejohn M, Yuen L, Edwards R, Devi U, Bowden S, et al. Molecular epidemiology of hepatitis delta virus in the Western Pacific region. J Clin Virol. 2014;61(1):34–9.
11. Braga WS, de Oliveira CM, de Araujo JR, Castilho Mda C, Rocha JM, Gimaque JB, et al. Chronic HDV/HBV co-infection: predictors of disease stage—a case series of HDV-3 patients. J Hepatol. 2014;61(6):1205–11. One of the earliest reports of HDV genotype 3 confirming the severity of HDV infection in that genotype.
12. Kay A, Melo da Silva E, Pedreira H, Negreiros S, Lobato C, Braga W, et al. HBV/HDV co-infection in the Western Brazilian Amazonia: an intriguing mutation among HDV genotype 3 carriers. J Viral Hepat. 2014;21(12):921–4.
13. Tsatsralt-Od B, Takahashi M, Nishizawa T, Endo K, Inoue J, Okamoto H. High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. J Med Virol. 2005;77(4):491–9.
14. Abbas Z. Hepatitis D, in Pakistan. J Coll Physicians Surg Pak. 2012;22(9):547–8.
15. Andernach IE, Leiss LV, Tarnagda ZS, Tahita MC, Otegbayo JA, Forbi JC, et al. Characterization of hepatitis delta virus in sub-Saharan Africa. J Clin Microbiol. 2014;52(5):1629–36.
16. Liao B, Zhang F, Lin S, He H, Liu Y, Zhang J, et al. Epidemiological, clinical and histological characteristics of HBV/HDV co-infection: a retrospective cross-sectional study in Guangdong, China. PLoS One. 2014;9(12), e115888.
17. Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. 2012;32(3):228–36.
18. Gaeta GB, Stroffolini T, Chiaramonte M, Ascione T, Stornaiuolo G, Lobello S, et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology. 2000;32(4 Pt 1):824–7.
19. Degertekin H, Yalcin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int. 2008;28(4):494–8.
20. Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection—not a vanishing disease in Europe! Hepatology. 2007;45(5):1331–2. author reply 1332–3.
21. Le Gal F. C. Castelneau ea. Hepatitis D virus infection—not a vanishing disease in Europe! Reply. Hepatology. 2007;45(5):1332–3.
22. Heidrich B, Deterding K, Tillmann HL, Raupach R, Manns MP, Wedemeyer H. Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat. 2009;16(12):883–94.
23. Erhardt A, Knuth R, Sagir A, Kirschberg O, Heintges T, Haussinger D. Socioepidemiological data on hepatitis delta in a German university clinic—increase in patients from Eastern Europe and the former Soviet Union. Z Gastroenterol. 2003;41(6):523–6.
24. Erhardt A, Hoernke M, Heinzel-Pleines U, Sagir A, Gobel T, Haussinger D. Retrospective analysis of chronic hepatitis D in a West German University Clinic over two decades: migratory pattern, prevalence and clinical outcome. Z Gastroenterol. 2010;48(8):813–7.
25. Kucirka LM, Farzadegan H, Feld JJ, Mehta SH, Winters M, Glenn JS, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis. 2010;202(6):845–52.
26. Soriano V, Grint D, d'Arminio Monforte A, Horban A, Leen C, Poveda E, et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS. 2011;25(16):1987–92.
27. Ippolito AM, Niro GA, Fontana R, Lotti G, Gioffreda D, Valvano MR, et al. Unawareness of HBV infection among inpatients in a Southern Italian hospital. J Viral Hepat. 2011;18(7):e206–11.
28. Flodgren E, Bengtsson S, Knutsson M, Strebkova EA, Kidd AH, Alexeyev OA, et al. Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains. J Clin Microbiol. 2000;38(9):3311–6.
29. Buti M, Homs M, Rodriguez-Frias F, Funalleras G, Jardi R, Sauleda S, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat. 2011;18(6):434–42.
30. Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, Olivero A, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol. 2010;53(5):834–40.
31. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136(5):1629–38.
32. Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006;130(6):1625–35.
33. Romeo R, Foglieni B, Casazza G, Spreafico M, Colombo M, Prati D. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS One. 2014;9(3), e92062. An interesting study predicting HDV RNA levels as marker of cirrhosis and liver cancer.
34. Calle Serrano B, Grosshennig A, Homs M, Heidrich B, Erhardt A, Deterding K, et al. Development and evaluation of a baseline-event-anticipation score for hepatitis delta. J Viral Hepat. 2014;21(11):e154–63. One interesting study building a score which identified patients under risk of developing liver-related complications.
35. Fernandez-Montero JV, Vispo E, Barreiro P, Sierra-Enguita R, de Mendoza C, Labarga P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis. 2014;58(11):1549–53. Important study indicating high rates of death and liver decompensation in patients infected with hepatitis delta and HIV.
36. Grabowski J, Wedemeyer H. Hepatitis delta: immunopathogenesis and clinical challenges. Dig Dis. 2010;28(1):133–8.
37. Huang YH, Tao MH, Hu CP, Syu WJ, Wu JC. Identification of novel HLA-A*0201-restricted CD8+ T-cell epitopes on hepatitis delta virus. J Gen Virol. 2004;85(Pt 10):3089–98.
38. Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, Meyer MF, et al. Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat. 2006;13(8):505–14.
39. Lunemann S, Malone DF, Hengst J, Port K, Grabowski J, Deterding K, et al. Compromised function of natural killer cells in acute and chronic viral hepatitis. J Infect Dis. 2014;209(9):1362–73. This study suggested that disease activity is dependent on alteration of NK cell phenotype and function.
40. Lunemann S, Malone DF, Grabowski J, Port K, Beziat V, Bremer B, et al. Effects of HDV infection and pegylated interferon alpha treatment on the natural killer cell compartment in chronically infected individuals. Gut. 2015;64(3):469–82. A detailed study describing how HDV infection and IFN-α treatment affect the NK cell compartment and what consequences this has for the functional capacity of NK cells.
41. Grabowski J, Yurdaydin C, Zachou K, Buggisch P, Hofmann WP, Jaroszewicz J, et al. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. Liver Int. 2011;31(9):1395–405.
42. Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, et al. Anti-HDV IgM as a marker of disease activity in hepatitis delta. PLoS One. 2014;9(7), e101002. This study underlines the predictive character of anti-HDV IgM as a marker of disease activity.
43. Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int. 2010;30(3):430–7.
44. Schaper M, Rodriguez-Frias F, Jardi R, Tabernero D, Homs M, Ruiz G, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol. 2010;52(5):658–64.
45. Wedemeyer H. Re-emerging interest in hepatitis delta: new insights into the dynamic interplay between HBV and HDV. J Hepatol. 2010;52(5):627–9.
46. Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2006;43(1):100–7.
47. Heidrich B, Serrano BC, Idilman R, Kabacam G, Bremer B, Raupach R, et al. HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. Liver Int. 2012;32(9):1415–25. The first analysis distinguishing the clinical long-term outcome due to HBeAg status in patients infected with hepatitis delta.
48. Williams V, Brichler S, Radjef N, Lebon P, Goffard A, Hober D, et al. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J Gen Virol. 2009;90(Pt 11):2759–67.
49. Deterding K, Pothakamuri SV, Schlaphoff V, Hadem J, Metzler F, Bahr MJ, et al. Clearance of chronic HCV infection during acute delta hepatitis. Infection. 2009;37(2):159–62.
50. Benegiamo G, Vinciguerra M, Guarnieri V, Niro GA, Andriulli A, Pazienza V. Hepatitis delta virus induces specific DNA methylation processes in Huh-7 liver cancer cells. FEBS Lett. 2013;587(9):1424–8.
51. Mederacke I, Yurdaydin C, Dalekos GN, Bremer B, Erhardt A, Cakaloglu Y, et al. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-alpha2a treatment. Antivir Ther. 2012;17(2):305–12.
52. Mederacke I, Bremer B, Heidrich B, Kirschner J, Deterding K, Bock T, et al. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol. 2010;48(6):2022–9. One of several important reports that established the so far earliest novel automated HDV RNA assay.
53. Brichler S, Le Gal F, Butt A, Chevret S, Gordien E. Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia. Clin Gastroenterol Hepatol. 2013;11(6):734–40. Large analysis which revealed controversial quantification results of HDV RNA in African patients infected with strains of genotypes 1 and 5 to 8.
54. Niro GA, Gioffreda D, Fontana R. Hepatitis delta virus infection: open issues. Dig Liver Dis. 2011;43 Suppl 1:S19–24.
55. Katsoulidou A, Manesis E, Rokka C, Issaris C, Pagoni A, Sypsa V, et al. Development and assessment of a novel real-time PCR assay for quantitation of hepatitis D virus RNA to study viral kinetics in chronic hepatitis D. J Viral Hepat. 2013;20(4):256–62.
56. Botelho-Souza LF, dos Santos AO, Borzacov LM, Honda ER, Villalobos-Salcedo JM, Vieira DS. Development of a reverse transcription quantitative real-time PCR-based system for rapid detection and quantitation of hepatitis delta virus in the western Amazon region of Brazil. J Virol Methods. 2014;197:19–24.
57. Rizzetto M, Rosina F, Saracco G, Bellando PC, Actis GC, Bonino F, et al. Treatment of chronic delta hepatitis with alpha-2 recombinant interferon. J Hepatol. 1986;3 Suppl 2:S229–33.
58. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 1994;330(2):88–94.
59. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126(7):1740–9.
60. Gunsar F, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther. 2005;10(6):721–6.
61. Niro GA, Ciancio A, Tillman HL, Lagget M, Olivero A, Perri F, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther. 2005;22(3):227–32.
62. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology. 1999;117(5):1229–33.
63. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat. 2005;12(1):2–9.
64. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. 2006;44(3):728–35.
65. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44(3):713–20.
66. Erhardt A, Gerlich W, Starke C, Wend U, Donner A, Sagir A, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int. 2006;26(7):805–10.
67. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364(4):322–31. The so far largest study investigating the effect of interferon-based therapy in patients infected with hepatitis delta.
68. Ormeci N, Bolukbas F, Erden E, Coban S, Ekiz F, Erdem H, et al. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months. Hepato-Gastroenterology. 2011;58(110–111):1648–53.
69. Karaca C, Soyer OM, Baran B, Ormeci AC, Gokturk S, Aydin E, et al. Efficacy of pegylated interferon-alpha treatment for 24 months in chronic delta hepatitis and predictors of response. Antivir Ther. 2013;18(4):561–6.
70. Abbas Z, Memon MS, Mithani H, Jafri W, Hamid S. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience. Antivir Ther. 2014;19(5):463–8.
71. Heller T, Rotman Y, Koh C, Clark S, Haynes-Williams V, Chang R, et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther. 2014;40(1):93–104.
72. Heidrich B, Yurdaydin C, Kabacam G, Ratsch BA, Zachou K, Bremer B, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014;60(1):87–97. One important study demonstrating that late HDV RNA relapses may occur after PEG-IFN-α therapy and that therefore the term sustained virological response should be avoided in HDV infection. Nevertheless, patients responding to therapy showed lower rates of clinical events.
73. Wedemeyer H, Yurdaydın C, Caruntu FA, Curescu MG, Yalçın K, Akarca US, et al. Pegylated-interferon-alfa-2a plus tenofovir or placebo for the treatment of hepatitis delta. London: 49th Annual Meeting of the European Association for the Study of the Liver (EASL 2014); 2014. The most recent multicentric study of patients treated with PEG-IFN-α monotherapy or in combination with tenofovir.
74. Keskin O, Wedemeyer H, Tuzun A, Zachou K, Deda X, Dalekos GN, et al. Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome. Clin Gastroenterol Hepatol. 2015. One of several important analyses which identified HDV RNA levels at week 24 of treatment with PEG-IFN as a predictive marker of treatment response.
75. Yilmaz E, Baran B, Soyer OM, Onel M, Onel D, Ormeci AC, et al. Effects of polymorphisms in interferon lambda 3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection. Clin Gastroenterol Hepatol. 2014;12(10):1753–8.
76. Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, et al. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology. 2014;60(6):1902–10.
77. Wolters LM, van Nunen AB, Honkoop P, Vossen AC, Niesters HG, Zondervan PE, et al. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat. 2000;7(6):428–34.
78. Lau DT, Doo E, Park Y, Kleiner DE, Schmid P, Kuhns MC, et al. Lamivudine for chronic delta hepatitis. Hepatology. 1999;30(2):546–9.
79. Yurdaydin C, Bozkaya H, Onder FO, Senturk H, Karaaslan H, Akdogan M, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008;15(4):314–21.
80. Yurdaydin C, Bozkaya H, Gurel S, Tillmann HL, Aslan N, Okcu-Heper A, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol. 2002;37(2):266–71.
81. Garripoli A, Di Marco V, Cozzolongo R, Costa C, Smedile A, Fabiano A, et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver. 1994;14(3):154–7.
82. Kabacam G, Onder FO, Yakut M, Seven G, Karatayli SC, Karatayli E, et al. Entecavir treatment of chronic hepatitis D. Clin Infect Dis. 2012;55(5):645–50.
83. Calle Serrano B, Manns MP, Wedemeyer H. Hepatitis delta and HIV infection. Semin Liver Dis. 2012;32(2):120–9.
84. Sheldon J, Ramos B, Toro C, Rios P, Martinez-Alarcon J, Bottecchia M, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther. 2008;13(1):97–102.
85. Soriano V, Vispo E, Sierra-Enguita R, Mendoza C, Fernandez-Montero JV, Labarga P, et al. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. AIDS. 2014;28(16):2389–94. Long-term analysis of patients infected with hepatitis delta and HIV who were treated with tenofovir showing reduced HDV RNA levels.
86. Rosenau J, Kreutz T, Kujawa M, Bahr MJ, Rifai K, Hooman N, et al. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J Hepatol. 2007;46(4):635–44.
87. Smedile A, Casey JL, Cote PJ, Durazzo M, Lavezzo B, Purcell RH, et al. Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope. Hepatology. 1998;27(6):1723–9.
88. Mederacke I, Filmann N, Yurdaydin C, Bremer B, Puls F, Zacher BJ, et al. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. J Hepatol. 2012;56(1):115–22.
89. Giersch K, Helbig M, Volz T, Allweiss L, Mancke LV, Lohse AW, et al. Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection. J Hepatol. 2014;60(3):538–44. First mouse model demonstrating that HDV can persist intrahepatically and may convert to a productive infection.
90. Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest. 2003;112(3):407–14.
91. Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015. First 2A double-blind, randomised, placebo-controlled study assessing the effect of the prenylation inhibitor lonafarnib on patients infected with hepatitis delta.
92. Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014;147(1):48–64.
93. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Falth M, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014;146(4):1070–83. Important bioinformatic analyses of comparative expression arrays confirming that sodium-taurocholate co-transporter polypeptide is a specific receptor for HBV and HDV.
94. Urban S, Bogomolov P, Voronkova N, Allweiss L, Dandri M, Schwab M, et al. A proof-of-concept phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex B. Boston: 65th Annual Meeting of the American Association for the Study of Liver (AASLD 2014); 2014. One of the first studies analyzing the effect of HBV/HDV entry inhibitor Myrcludex B in patients infected with HDV.
95. Rizzetto M, Smedile A. Pegylated interferon therapy of chronic hepatitis D: in need of revision. Hepatology. 2015;61(4):1109–11.
96. Gheorghe L, Iacob S, Simionov I, Vadan R, Constantinescu I, Caruntu F, et al. Weight-based dosing regimen of peg-interferon alpha-2b for chronic hepatitis delta: a multicenter Romanian trial. J Gastrointestin Liver Dis. 2011;20(4):377–82.